GastroLab

Chronic Diarrhea is something many people learn to live with. But it is not normal, and it is certainly not something you should ignore.

Behind the symptoms, there may be a treatable cause. The key is to look beyond assumptions and find out what your gut is really trying to say. Not every chronic Diarrhea is IBS.

If symptoms persist, speak to your doctor and ask about the possible causes and tests that can help.

Because understanding the problem is the first step toward solving it.

A recent article published in April 2026 in the prestigious Helicobacter describes the HOPE Hp-GC Project, an important Latin American effort to build an organized gastric cancer prevention program in intermediate-to-high-incidence regions.

The study was initiated in Chile where their practical public-health challenge was clear:

How can gastric cancer prevention be implemented in settings where universal endoscopic screening is difficult to deliver at scale?

The HOPE model addresses this through two age-specific strategies:

For individuals aged 30–39 years, the focus is primary prevention through H. pylori screening, treatment, and eradication confirmation.

For individuals aged 40–75 years, the model combines primary and secondary prevention using non-invasive gastric biomarkers, clinical variables, risk stratification, and prioritized high-quality endoscopy.

In the Chilean validation cohort (n=866) , an algorithm based on captured 80.6% of OLGA III–IV cases and 100% of /high-grade dysplasia cases in higher-priority groups. No low-grade dysplasia, high-grade dysplasia, or gastric cancer was identified in the low-risk priority groups.

The pilot also reported an 87% in the endoscopy waiting list at Santa Rosa de Molina Hospital.

This project was important as it showed a way from biomarker reporting to biomarker-guided gastric cancer prevention pathways.

The article does brings out a key point that non-invasive biomarkers are most powerful when they are not treated as merely laboratory values, but integrated into structured prevention pathways for endoscopy prioritization, and long-term surveillance planning.

Shouldn’t gastric cancer prevention move towards this path?

Reach out to us at [email protected] to know more on Gastropanel and Hpylori diagnostics or if you wish to use it in your clinical practice.

Article link: https://onlinelibrary.wiley.com/doi/abs/10.1111/hel.70109

WDHD2026
Chronic diarrhea demands better diagnosis, not more trials.
May 29 marks World Digestive Health Day and throughout this month of May we’ll be focusing on chronic diarrhea; its hidden drivers, and how at GastroLab we are closing the diagnostic gap through innovations and tests that are aligned to demographic and epidemiological needs of India. More insights coming soon.

WORLD DIGESTIVE HEALTH DAY 2026
Chronic diarrhea is often approached as a label rather than a mechanism.

But inflammation, malabsorption, bile acid dysfunction, motility disorders, microbiome alterations, and gut-brain dysregulation can all produce similar symptom patterns.

The challenge is not simply treating diarrhea BUT TO IDENTIFY the dominant physiological pathway driving it.

And a mechanism based approach may change both diagnostics and therapy.

WATCH THIS SPACE FOR MORE as we approach the world digestive disease day 2026 the theme for which is chronic diarrhea we attempt to identify diagnostic gaps thoughout this month.

Come join us to spread the message…

(CRC) is rising at an alarming rate in India, now ranking as the country's fourth most common cancer.

Colon Cancer demographics are shifting in India with up to 40% of patients now under the age of 40. In such settings routine early screening is critical.

But are we using the most effective tests?

Standard FIT testing has a biological blind spot: Hemoglobin degrades during colonic transit, which often leads to missed right-sided (proximal) tumors.

The ColonView Dual Biomarker FIT

It detects both Human Hemoglobin (Hb) AND the highly stable Hb/Hp Complex.
ColonView resists degradation and captures the signals that standard FIT misses.

📊 The Clinical Advantage:

✅ 100% detection of proximal neoplasia & carcinoma in study cohorts

✅ No dietary restrictions (significantly better patient compliance)

✅ 15-minute rapid results from a single sample

Screening isn't just about detecting blood; it's about detecting the right biological signal. It's time to eliminate diagnostic blind spots.

📩 Reach out to [email protected] to integrate ColonView into your clinical practice or Labs today.

🚨Attention please🚨

Fresh off the press!

A game changing study done at AIIMS under the guidance of Dr. Govind K. Makharia on chronic diarrhea and Bile Acid Malabsorption (BAM) has just been published in the Indian Journal of Gastroenterology and we at GastroLab India Pvt. Ltd are proud to have supported this incredibly important study.

"Could a single spot stool sample be the key to unlocking the hidden cause of chronic diarrhea for millions of patients?"

For years, diagnosing BAM has been a major clinical challenge. The gold standard test (75SeHCAT) is costly, requires radiation, and isn't widely available outside Europe. As a result, BAM is often missed in patients with chronic diarrhea.

But what if a single stool sample could change that?

This pilot observational study evaluated the IDK® Bile Acid test, a simple enzymatic spectrophotometric assay to measure total stool bile acids in a single spot sample.

Here are the steaming hot findings:

✅ High Accuracy:

An optimal f***l bile acid (FBA) cut-off of 2.8 µmol/g yielded 89.5% sensitivity and 92.0% specificity.

✅ High Prevalence Discovered:

BAM was identified in:

• 88.1% of patients with ileal 's disease

• 57.0% of post- patients

• 54.5% of patients

• 21.0% of -D and functional patients

The authors concluded that

“single spot FBA estimation……… may be a promising tool for diagnosing BAM in patients with chronic diarrhea, especially in low-resource settings….. Increasing use
of spot FBA may help diagnose more patients with BAM and
improve management of chronic diarrhea considerably. “

We finally have a promising, simple, and accessible diagnostic tool for BAM. This could help avoid inappropriate treatment and offer targeted relief for patients suffering from chronic diarrhea.

At GastroLab India Pvt. Ltd , we are committed to closing diagnostic gaps in Indian healthcare through state of the art, epidemiologically relevant testing solutions.

Share ♻️ this pathbreaking research

Link to article 👇🏽👇🏽

Mehta, S., Agarwal, S., Pachisia, A.V. et al. A single test strategy using spot f***l bile acid test may be a feasible strategy for the diagnosis of bile acid malabsorption. Indian J Gastroenterol (2026).

https://doi.org/10.1007/s12664-026-01972-y

A single test strategy using spot f***l bile acid test may be a feasible strategy for the diagnosis of bile acid malabsorption - Indian Journal of Gastroenterology Background Bile acid malabsorption (BAM) is often missed in patients with chronic diarrhea as diagnostic tests are technically challenging and not available widely. Quantitative estimation of f***l bile acids (FBA) in a single stool sample has been reported recently for the diagnosis of BAM and may....